DeepkinetiX

What DeepkinetiX does

DeepkinetiX is a Cambridge, MA-based private biotech software company founded in 2024 that has built KinetixFlow™, a cloud-native biosimulation platform that combines AI-driven pharmacokinetic (PK) analysis with mechanistic Quantitative Systems Pharmacology (QSP) modeling to support drug development decision-making. The platform integrates protocolized human-relevant data intake, a hybrid SAEM/FOCE-ELS population PK/PD modeling engine, 80+ pre-built model templates spanning modalities including ADCs, bispecifics, PROTACs, and gene therapies, and proprietary dual elimination pathway (k20) modeling that the company reports yields 121- and 187-point AIC improvements over industry-standard tools in mAb and free-payload analyses where competing software fails to converge. Its product surface is structured as a core platform with two modular add-ons: the PK Analytics Suite, which delivers automated, audit-ready NCA reports in under 24 hours, and the Digital Trial Engine, which combines patient-derived 3D assay data with AI-driven QSP to forecast efficacy, safety, and dose before Phase I.

Outputs are NAM-aligned, FDA Modernization Act 2.0-focused, and CFR 21 Part 11 compliant for IND/NDA submissions. The company targets three primary customer segments — Contract Research Organizations (CROs) seeking to scale internal PK analysis without headcount, biotech companies needing earlier de-risking of novel therapeutics, and pharmaceutical companies standardizing pharmacometric workflows — with a secondary academic/hospital researcher segment. Go-to-market combines direct enterprise sales (Request a Demo, Book a Demo) with product-led growth (free trials, sample reports, pilot programs) and a credit-based, pay-as-you-go SaaS pricing model with no upfront costs, licenses, or hardware requirements. Distribution is supplemented by an R&D partner network that includes Preclinix, AIM Biotech, Apricell Biotechnology, L2P Research, Nomocan Pharmaceuticals, Mass General Brigham, and Scientist.com, plus a flagship partnership with TradeCraft Clinical Research (May 2026) positioned as the industry's first System of Record for PK execution. The company operates with a small team of 6 visible members plus a 6-person advisory board, has not publicly disclosed funding rounds or revenue, and markets primarily through content-led channels (blog, newsletter, LinkedIn, X).

Name

DeepkinetiX

Legal name

DeepkinetiX

Website

https://deepkinetix.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

DeepkinetiX is a Cambridge, MA-based private biotech software company (founded 2024) that offers KinetixFlow™, a cloud-native AI-driven platform combining pharmacokinetic analysis, mechanistic QSP modeling, and preclinical digital twins, targeting CROs, biotechs, and pharma for IND/NDA-ready drug development decision support.

Ownership category

akta.pro rank

Product category

Drug Development Software

NAICS

Software Publishers (5132), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Biosimulation software
• Pharmacokinetic modeling
• Drug development platform
• Quantitative systems pharmacology
• Preclinical drug testing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscription: Cloud-native platform accessed via subscription with credit-based pricing. Users pay only for what they use through a credit system, with no upfront costs, licenses, or hardware required.
2. PK Analytics Services: Contract research solutions for NCA and PK analysis delivered through the platform, with turnaround times under 24 hours for IND/NDA-ready reports.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

DeepkinetiX sells KinetixFlow, an AI-powered, cloud-native biosimulation platform that combines automated pharmacokinetic (PK) analytics with quantitative systems pharmacology (QSP) modeling to compress preclinical-to-clinical drug development timelines. The platform replaces fragmented spreadsheets and legacy desktop PK tools with a unified execution environment for PK analysis, population PK/PD modeling, and digital trial simulation. Customers subscribe to the platform to run NAM-aligned biosimulation workflows across preclinical and translational phases.

Product overview

DeepkinetiX offers KinetixFlow™, a unified cloud-native platform for AI-powered drug development and biosimulation. The platform is structured as a core product (KinetixFlow™) with modular add-on capabilities: the PK Analytics Suite for automated NCA and PK modeling, and the Digital Trial Engine for predictive QSP biosimulation and preclinical digital twins. The platform combines mechanistic modeling with human-relevant data to improve translational confidence across development stages, aligned with FDA New Approach Methodologies (NAMs).

Differentiator

Problem solved

Functional benefit

Brands

• KinetixFlow™: Cloud-native biosimulation platform integrating governed PK and QSP modeling with structured human-relevant data for regulatory-ready drug development decisions.
• PK Analytics Suite
• Digital Trial Engine

Products and services

• KinetixFlow Platform

Quantifiable outcome

• NCA reports delivered in under 24 hours vs. traditional multi-week timelines
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

13 partnerships are on record, tiered core and minor.

• TradeCraft Clinical ResearchcoreStrategic or Co-development Partner · 18 May 2026Partnership to deliver the industry's first System of Record for PK execution. Combines DeepkinetiX's execution layer with TradeCraft's total control of data for fully connected workflow from PK execution through downstream study delivery.
• PreclinixminorStrategic or Co-development PartnerR&D partner providing research services. Ensuring results are reproducible, credible, and ready for regulatory translation.
• AIM BiotechminorStrategic or Co-development PartnerR&D partner providing research services. Ensuring results are reproducible, credible, and ready for regulatory translation.
• Apricell BiotechnologyminorStrategic or Co-development PartnerR&D partner providing research services. Ensuring results are reproducible, credible, and ready for regulatory translation.
• L2P ResearchminorStrategic or Co-development PartnerR&D partner providing research services. Ensuring results are reproducible, credible, and ready for regulatory translation.
• Nomocan PharmaceuticalscoreStrategic or Co-development PartnerStrategic partner in early-stage oncology programs. Using QSP, mechanistic modeling, and AI analytics to explore drug behavior and immune dynamics before clinical development.
• Mass General BrighamminorStrategic or Co-development PartnerR&D partner providing research services through major healthcare system. Ensuring results are reproducible, credible, and ready for regulatory translation.
• Scientist.comminorChannel Partner/ Reseller/ DistributorR&D partner and marketplace for research services. Ensuring results are reproducible, credible, and ready for regulatory translation.
• CIC (Cambridge Innovation Center)minorStrategic or Co-development PartnerInnovation center partner providing company headquarters location and startup ecosystem support.
• MahiminorStrategic or Co-development PartnerStrategic partner in the innovation ecosystem.
• C10minorStrategic or Co-development PartnerStrategic partner and innovation lab supporting company growth.
• Foley HoagminorImplementation/ SI/ Consulting PartnerLegal and business advisory partner providing regulatory and strategic counsel.
• MTI (Mass Technology Innovation)minorStrategic or Co-development PartnerStrategic partner supporting technology innovation and ecosystem development.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Certara: Certara is the dominant pharmacometrics and biosimulation platform provider (Phoenix WinNonlin, PKSim, ModSim). It competes directly with DeepkinetiX in NCA, population PK/PD, and QSP workflows for CRO and pharma customers, with a deep regulatory-validated install base.
• Simulations Plus: Simulations Plus provides PBPK, QSP, and population PK software (GastroPlus, ADMET Predictor, MonolixSuite) plus DMPK services. It is the most direct competitor to DeepkinetiX's mechanistic PK/QSP offering, especially in preclinical-to-clinical translation.

Emerging players

• CytoReason: CytoReason is an AI-driven QSP and disease-modeling platform used by pharma for immunology and oncology indication selection. It overlaps with DeepkinetiX's QSP/Digital Trial Engine but focuses on disease modeling rather than PK execution.
• GNS Healthcare: GNS Healthcare applies AI/causal models to build patient-level digital twins for oncology and immunology programs. It is comparable to DeepkinetiX's Digital Trial Engine on the patient-derived simulation front, though GNS focuses on real-world data and clinical rather than preclinical PK.
• Metrum Research Group: Metrum Research Group provides pharmacometrics services and open-source tooling (mrgsolve) for population PK/PD and QSP. It is comparable to DeepkinetiX on the modeling methodology side and competes for the same CRO/biotech modeling-services spend.
• Insilico Medicine: Insilico Medicine operates AI-driven drug discovery and clinical pharmacology platforms (PandaOmics, Chemistry42, InClinico). It overlaps with DeepkinetiX's positioning around AI-powered drug development and clinical trial outcome prediction.

Broad incumbents

• Schrödinger: Schrödinger operates a broader computational chemistry and predictive modeling platform with live chemistry, FEP+, and biologics capabilities. While not a direct NCA/PK competitor, it overlaps in AI-driven drug development decision support for pharma.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI to drive preclinical drug discovery. It overlaps with DeepkinetiX in AI-enabled preclinical decision-making, though Recursion is also an asset-owning biotech rather than a pure software vendor.
• Dotmatics: Dotmatics (now part of Siemens) provides scientific informatics (LIMS, ELN, data platform) broadly across life sciences R&D. It is adjacent to DeepkinetiX as upstream/downstream data infrastructure that could integrate with KinetixFlow in CRO workflows.
• Evidera (PPD / Thermo Fisher): Evidera provides model-informed drug development services, including PK/PD and regulatory strategy, as part of Thermo Fisher's PPD CRO. It competes with DeepkinetiX for CRO-led modeling engagements and represents a services-led alternative to DeepkinetiX's SaaS approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/deepkinetix

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepkinetiX